BACKGROUND: Adequate local control rates > 90% and acceptable functional results are the paramount goals in the treatment of soft-tissue sarcoma. Purpose of this paper is to evaluate response, long-term control, functional outcome and toxicity following neoadjuvant radiochemotherapy (RCT) in advanced and recurrent soft tissue sarcoma. PATIENTS AND METHODS: Between 1992 and 1998, a total of 23 patients in whom primary curative limb and function sparing surgery seemed impossible entered the study. Sixteen patients had primary and 7 patients recurrent sarcoma. The stages according to AJCC/UICC 1997 were as follows: rIA (2), rIIA (5) IIA (4), IIB (2), III (7), IV (3). RCT consisted of an accelerated split-course radiation (1.5 to 1.6 Gy twice daily, median total dose 60 Gy, range 60 to 64 Gy, break of 1 week after 30 Gy) with concomitant chemotherapy using adriamycin (50 mg/m2/d on days 2 and 30) and ifosfamide (1.5 g/m2/d on days 1 to 5, 29 to 33). Median follow-up was 26 months (range 2 to 92 months). RESULTS: Twenty-two patients underwent surgery with a curative (R0) resection being achieved in 20/22 (91%) patients and gross residual (R2) tumor or unclear tumor margins (RX) in 1 patient, respectively. Effective tumor-downstaging was documented in 4/22 (18%) patients (ypT0: 3 patients, ypT1: 1 patient). Long-term local tumor control after R0/RX resection remained 100%. Without prognostic impact on tumor response and local control have been the variables primary vs. recurrent tumor, grading, stage and gender. Delayed wound healing was only noted in 1/22 (5%) patients. Four patients developed distant metastases. Overall-, NED- and distant-metastases-free survival rates were 83%, 64% and 68%, respectively, at 3 years. Grade 3/4 neutropenia (WHO) was seen after 21/46 (46%) cycles of chemotherapy with 1 patient dying of septicemia. The functional results were good to excellent in 18/22 (82%) patients. CONCLUSION: Accelerated split-course radiation with 60 to 64 Gy and concurrent chemotherapy using adriamycin/ifosfamide is a safe and effective treatment for soft tissue sarcoma. This regimen may be considered in all cases with recurrent and advanced disease not amenable to primary curative or limb sparing surgery.
BACKGROUND: Adequate local control rates > 90% and acceptable functional results are the paramount goals in the treatment of soft-tissue sarcoma. Purpose of this paper is to evaluate response, long-term control, functional outcome and toxicity following neoadjuvant radiochemotherapy (RCT) in advanced and recurrent soft tissue sarcoma. PATIENTS AND METHODS: Between 1992 and 1998, a total of 23 patients in whom primary curative limb and function sparing surgery seemed impossible entered the study. Sixteen patients had primary and 7 patients recurrent sarcoma. The stages according to AJCC/UICC 1997 were as follows: rIA (2), rIIA (5) IIA (4), IIB (2), III (7), IV (3). RCT consisted of an accelerated split-course radiation (1.5 to 1.6 Gy twice daily, median total dose 60 Gy, range 60 to 64 Gy, break of 1 week after 30 Gy) with concomitant chemotherapy using adriamycin (50 mg/m2/d on days 2 and 30) and ifosfamide (1.5 g/m2/d on days 1 to 5, 29 to 33). Median follow-up was 26 months (range 2 to 92 months). RESULTS: Twenty-two patients underwent surgery with a curative (R0) resection being achieved in 20/22 (91%) patients and gross residual (R2) tumor or unclear tumor margins (RX) in 1 patient, respectively. Effective tumor-downstaging was documented in 4/22 (18%) patients (ypT0: 3 patients, ypT1: 1 patient). Long-term local tumor control after R0/RX resection remained 100%. Without prognostic impact on tumor response and local control have been the variables primary vs. recurrent tumor, grading, stage and gender. Delayed wound healing was only noted in 1/22 (5%) patients. Four patients developed distant metastases. Overall-, NED- and distant-metastases-free survival rates were 83%, 64% and 68%, respectively, at 3 years. Grade 3/4 neutropenia (WHO) was seen after 21/46 (46%) cycles of chemotherapy with 1 patient dying of septicemia. The functional results were good to excellent in 18/22 (82%) patients. CONCLUSION: Accelerated split-course radiation with 60 to 64 Gy and concurrent chemotherapy using adriamycin/ifosfamide is a safe and effective treatment for soft tissue sarcoma. This regimen may be considered in all cases with recurrent and advanced disease not amenable to primary curative or limb sparing surgery.
Authors: T A Brant; J T Parsons; R B Marcus; S S Spanier; T C Heare; R A van der Griend; W F Enneking; R R Million Journal: Int J Radiat Oncol Biol Phys Date: 1990-10 Impact factor: 7.038
Authors: K Antman; J Crowley; S P Balcerzak; S E Rivkin; G R Weiss; A Elias; R B Natale; R M Cooper; B Barlogie; D L Trump Journal: J Clin Oncol Date: 1993-07 Impact factor: 44.544
Authors: J C Yang; A E Chang; A R Baker; W F Sindelar; D N Danforth; S L Topalian; T DeLaney; E Glatstein; S M Steinberg; M J Merino; S A Rosenberg Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: P W Pisters; S R Patel; D G Varma; S C Cheng; N P Chen; H T Nguyen; B W Feig; A Pollack; R E Pollock; R S Benjamin Journal: J Clin Oncol Date: 1997-12 Impact factor: 44.544
Authors: C Cordon-Cardo; E Latres; M Drobnjak; M R Oliva; D Pollack; J M Woodruff; V Marechal; J Chen; M F Brennan; A J Levine Journal: Cancer Res Date: 1994-02-01 Impact factor: 12.701
Authors: Thomas Brodowicz; Gabriele Amann; Andreas Leithner; Arpad Sztankay; Franz Kainberger; Wolfgang Eisterer; Bernadette Liegl-Atzwanger; Franz Rachbauer; Thomas Rath; Michael Bergmann; Philipp T Funovics; Ferdinand Ploner; Reinhard Windhager Journal: Wien Klin Wochenschr Date: 2011-10-28 Impact factor: 1.704
Authors: A Willner; K Fechner; A Agaimy; F Haller; M Eckstein; O J Ott; F Putz; U S Gaipl; S Kersting; N Meidenbauer; R Grützmann; R Fietkau; S Semrau Journal: Strahlenther Onkol Date: 2021-11-04 Impact factor: 3.621